https://www.selleckchem.com/pr....oducts/asciminib-abl
Both groups were comparable with respect to the baseline volume (p = 0.135). Nevertheless, the nodular volume reduction rate was significantly different at 3-month follow-up (study group 56.97 ±11.39%, control group 47.07 ±7.93%; p = 0.003) and 6-month follow-up (study group 78.38 ±8.91%, control group 69.54 ±9.41%; p = 0.004). In both groups, cosmetic and symptom scores decreased progressively (p 0.005) and there were no major complications. Thyroid hormones and antibodies were within normal limits before the procedure, a
Like
Comment
Share
